Despite advances in the diagnostic and therapeutic modalities, the prognosis of several solid tumor malignancies remains poor. Different factors associated with solid tumors including a varied genetic ...

Specifically in solid tumors, tumor associated macrophages (TAMs ... They generally produce growth factors, chemokines, and matrix metalloproteinases (MMPs), which act directly on cancer cells or in ...

For solid tumors, however, the efficacy of CAR T-cell treatments has been limited and progress “more incremental,” Christian Hinrichs, MD, with Rutgers Cancer Institute in New Brunswick ...

Bolt Biotherapeutics, Inc., announced today that the target of their worldwide co-development collaboration with Toray Industries, Inc. is Caprin-1, a novel cancer target discovered by Toray. The ...

The combination therapy using chemokines as the main component are ... effects and complete eradication of the established solid tumors [89] CCL21 + mitomycin C Breast cancer MCF-7 cells ...

This will help advance the field of organoid-based cancer models." The review on tissue dissociation techniques is poised to make a significant impact on oncology research, especially for solid ...

However, CAR-T cell application in solid tumors remains challenging. There is an unmet clinical need for better cellular therapies for solid tumors. The team of researchers, led by Xiaowei ...

The subcutaneous formulation of Opdivo provides a convenient alternative to intravenous administration for patients with solid tumors, maintaining efficacy and safety. The CHECKMATE-67T trial ...

The study, published in Cell, shows that tumors drive clot formation (thrombosis) by releasing chemokines, secreted proteins which then circulate to the lung. Once there, the chemokines prompt ...

INCB-161734 is under clinical development by Incyte and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate (PTSR) ...